Clinical trial
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab…
NCT00398567 · Puma Biotechnology, Inc., Industry · Completed
Key facts
| NCT number | NCT00398567 |
|---|---|
| Title | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer |
| Official title | A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer |
| Lead sponsor | Puma Biotechnology, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | HKI-272, trastuzumab |
| Enrollment | 45 |
| Start date | Apr 4, 2007 |
| Primary completion | Jul 31, 2009 |
| Completion | Mar 2, 2018 |
| First posted | Nov 10, 2006 |
| Last update posted | Jul 24, 2018 |
| Countries | China, France, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: